世界のデジタルバイオマーカー市場2022-2030:種類別(ウェアラブル、モバイルアプリケーション、センサー)、臨床診療別、治療領域別、最終用途別、地域別

【英語タイトル】Digital Biomarkers Market Size, Share & Trends Analysis Report By Type (Wearable, Mobile based Applications, Sensors), By Clinical Practice, By Therapeutic Area, By End-use, By Region, And Segment Forecasts, 2022 - 2030

Grand View Researchが出版した調査資料(GRV22NV029)・商品コード:GRV22NV029
・発行会社(調査会社):Grand View Research
・発行日:2022年10月25日
・ページ数:150
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥880,600見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥1,028,600見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥1,324,600見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Grand View Research社は、世界のデジタルバイオマーカー市場規模が、2022年から2030年の間に年平均21.9%成長し、2030年までに13,966.16百万ドルに達すると予測しています。当調査レポートでは、デジタルバイオマーカーの世界市場について総合的に調査・分析を行い、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、競争状況、種類別(ウェアラブル、モバイルアプリケーション、センサー、その他)分析、臨床診療別(診断用、モニタリング用、予測・予知用、その他)分析、治療領域別(心血管&代謝障害(CVMD)、呼吸器疾患、精神疾患、睡眠&運動障害、その他疾患)分析、エンドユーザー別(医療系企業、医療提供者、医療費支払人、その他)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、企業情報などの構成でまとめています。なお、当書に掲載されている企業情報には、ActiGraph LLC、AliveCor Inc、Koneksa、Amgen Inc.、Biogen Inc.、Altoida Inc、IXICO plc、Adherium Limited、Empatica Inc、Huma、VivoSense、ResApp (Pfizer)などが含まれています。
・調査手法・範囲
・エグゼクティブサマリー
・市場変動・動向・範囲
・競争状況
・世界のデジタルバイオマーカー市場規模:種類別
- ウェアラブル型デジタルバイオマーカーの市場規模
- モバイルアプリケーション型デジタルバイオマーカーの市場規模
- センサー型デジタルバイオマーカーの市場規模
- その他デジタルバイオマーカーの市場規模
・世界のデジタルバイオマーカー市場規模:臨床診療別
- 診断用デジタルバイオマーカーの市場規模
- モニタリング用デジタルバイオマーカーの市場規模
- 予測・予知用デジタルバイオマーカーの市場規模
- その他デジタルバイオマーカーの市場規模
・世界のデジタルバイオマーカー市場規模:治療領域別
- 心血管&代謝障害(CVMD)における市場規模
- 呼吸器疾患における市場規模
- 精神疾患における市場規模
- 睡眠&運動障害における市場規模
- その他疾患における市場規模
・世界のデジタルバイオマーカー市場規模:エンドユーザー別
- 医療系企業における市場規模
- 医療提供者における市場規模
- 医療費支払人における市場規模
- その他エンドユーザーにおける市場規模
・世界のデジタルバイオマーカー市場規模:地域別
- 北米のデジタルバイオマーカー市場規模
- ヨーロッパのデジタルバイオマーカー市場規模
- アジア太平洋のデジタルバイオマーカー市場規模
- 中南米のデジタルバイオマーカー市場規模
- 中東・アフリカのデジタルバイオマーカー市場規模
・企業情報

Digital Biomarkers Market Growth & Trends

The global digital biomarkers market size is expected to reach USD 13,966.16 million by 2030, registering a CAGR of 21.9% during the forecast period, according to a new report by Grand View Research, Inc. Due to the rising acceptance of recent advancements and remote technologies, the market for digital biomarkers is anticipated to expand throughout the forecast period. Development of the remote data collecting technologies, which make up the largest segment of the market for digital biomarkers, has been propelled by the improvements in wearable and mobile technology. Additionally, this market segment is being further assisted by the growing use of the internet.

Vocal digital biomarkers in particular have lately come into existence and offer enormous business development potential. They enable easy data collection through voice recordings and through patient-owned technology like cell phones, wearables, and other devices. Vocal biomarkers are being utilized more frequently, which might ease the strain on the healthcare systems and improve patient outcomes by enhancing early intervention and before-time identification of physical or mental illnesses, boosting the market’s expansion during the forecast period.

Furthermore, in order to acquire market presence and further boost its revenue market share during the forecast, players have also begun exploring the vocal digital biomarkers. For instance, in October 2021, Sonde health launched a voice-enabled mental fitness monitoring technology platform.

Additionally, the market is anticipated to experience substantial expansion during the forecast period due to the rising prevalence of chronic diseases and neurodegenerative diseases, as well as the growing need for enhanced drug development to successfully control these diseases. In comparison to the conventional clinical trial process, digital biomarkers accelerate the development of new drugs.

According to a study by one of the well-known decentralized trial platform providers, Med able, 85.0% of all clinical trials experience some sort of delay, with the financial impact of delays costing between USD 600,000 and USD 8 million per day, decentralized clinical trials could save up to 1 to 3 months of time in phase 2 studies. As a result, medicine manufacturers are spending money on a digital biomarker for DCT, which is anticipated to fuel market expansion. For instance, AstraZeneca stated in March 2022 that it had invested USD 33.0 million in Huma, a UK-based company that provides decentralized clinical trials based on remote digital biomarkers. Through this alliance, the company will quicken the adoption of DCT.

Forward-thinking market participants are expanding their decisions and moving beyond typical suppliers in order to strengthen the company’s position in the global market for digital biomarkers by utilizing the wide range of technology capabilities and services required for future success. These companies have employed a variety of strategies such as product launches, joint ventures, and mergers & acquisitions. For instance, in April 2022, Pfizer acquired ResApp, an Australian- based startup that had created an app that uses artificial intelligence to gauge and determine the severity of respiratory problems using the coughing voice of a patient.

Digital Biomarkers Market Report Highlights

• Cardiovascular and metabolic disorders (CVMD) had the highest revenue share of more than 20.0% in the therapeutic area segment in 2021 and is anticipated that it will continue to have a significant major presence given the rising prevalence of cardiovascular diseases among patient populations around the globe. On the other hand, due to COVID-19 and emerging new technologies, it is anticipated that during the forecast period, market revenue share for respiratory disorders will expand at the fastest rate

• Due to the growing use of diagnostic monitoring meant for clinical disease and daily living, diagnostic digital biomarkers had the largest revenue share in the clinical practice segment in 2021. Moreover, the fastest revenue growth is anticipated for monitoring digital biomarkers during the forecast period

• Wearable had a revenue share of more than 39.0% in the digital biomarker type segment in 2021, due to the release of new, cutting-edge wearable smart watches and other products. As a result of the extensive usage of smartphones, worldwide, it is anticipated that revenue share growth for mobile-based applications would happen at the fastest rate during the forecast period. Additionally, rising usage of new technologies, and sensors, would also confront intense competition during the forecast period

• Healthcare companies hold the largest, more than 50.0% market share within the end-use category, in 2021, as a result of the rising indications and demands for cost-effective clinical trial and product analysis strategies

• North America dominated the market in 2021 and generated more than 59.0% share of the total revenue, as a result of its well-established advanced healthcare infrastructure and large expenditure in R&D activities. Furthermore, Europe would see the fastest rate of growth during the forecast period

• By engaging in partnerships, acquisitions, mergers, and product launches, key companies also help the market to expand. For instance, in 2021, Med able collaborated with the digital biomarkers business Aural Analytics to measure distant speech patterns and monitor their well-being and stage of decline

❖ レポートの目次 ❖

Table of Contents

Chapter 1 Research Methodology & Scope
1.1 Market Segmentation & Scope
1.1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 Report Objectives
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Digital BiomarkersMarket Summary, 2021
Chapter 3 Digital Biomarkers Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Digital Biomarkers Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Increased Popularity of Recent Innovations and Remote Technologies
3.3.1.2 Rising Usage of Smartphones and The Emergence of New Wearables
3.3.1.3 Expanding Therapeutic Area Application
3.3.1.4 Increasing Investment in Decentralized Clinical Trials
3.3.2 Market Restraints Analysis
3.3.2.1 Concerns about Data Privacy
3.3.2.1 Lack of Awareness and Poor Skilled Professionals in Emerging Economics
3.4 Digital Biomarkers Market Analysis Tools: Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Threat Of Substitutes
3.4.4 Threat Of New Entrants
3.4.5 Competitive Rivalry
3.5 Pestel Analysis
3.5.1 Political & Legal Landscape
3.5.2 Social Landscape
3.5.3 Technology Landscape
3.5.4 Environmental Analysis
3.6 Regulatory Framework
3.7 Technology Overview
3.8 Pricing Analysis
3.9 Covid-19 Impact Analysis
3.9.1 Current And Future Impact Analysis
3.9.2 Impact Of Covid-19 On Market Players
Chapter 4 Competitive Landscape
4.1 Market participation categorization
4.2 Public Companies
4.2.1 Company Market Position Analysis
4.2.2 Synergy Analysis: Major Deals & Strategic Alliances
4.3 Detailed list of market players
Chapter 5 Digital Biomarkers Market: Segment Analysis, by type, 2017 – 2030 (USD Million)
5.1 Type Movement Analysis, 2021 & 2030
5.1.1 Wearable
5.1.1.1 Wearable Market Estimates and Forecasts, 2017 – 2030 (Million)
5.1.2 Mobile Based Applications
5.1.2.1 Mobile Based Applications Market Estimates and Forecasts, 2017 – 2030 (Million)
5.1.3 Sensors
5.1.3.1 Sensors Market Estimates and Forecasts, 2017 – 2030 (Million)
5.1.4 Others
5.1.4.1 Others Market Estimates and Forecasts, 2017 – 2030 (Million)
Chapter 6 Digital Biomarkers Market: Segment Analysis, by Clinical Practice, 2017 – 2030 (USD Million)
6.1 Clinical Practice Movement Analysis, 2021 & 2030
6.1.1 Diagnostic Digital Biomarkers
6.1.1.1 Diagnostic Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
6.1.2 Monitoring Digital Biomarkers
6.1.2.1 Monitoring Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
6.1.3 Predictive and Prognostic Digital Biomarkers
6.1.3.1 Predictive and Prognostic Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
6.1.4 Others
6.1.4.1 Others Market Estimates and Forecasts, 2017 – 2030 (Million)
Chapter 7 Digital Biomarkers Market: Segment Analysis, by Therapeutic Area, 2017 – 2030 (USD Million)
7.1 Therapeutic Area Movement Analysis, 2021 & 2030
7.1.1 Cardiovascular and Metabolic Disorders (CVMD)
7.1.1.1 Cardiovascular and Metabolic Disorders (CVMD) Market Estimates and Forecasts, 2017 – 2030 (Million)
7.1.2 Respiratory Disorders
7.1.2.1 Respiratory Disorders Market Estimates and Forecasts, 2017 – 2030 (Million)
7.1.3 Psychiatric Disorders
7.1.3.1 Psychiatric Disorders Market Estimates and Forecasts, 2017 – 2030 (Million)
7.1.4 Sleep & Movement Disease
7.1.4.1 Sleep & Movement Disease Market Estimates and Forecasts, 2017 – 2030 (Million)
7.1.5 Neurological Disorders
7.1.5.1 Neurological Disorders Market Estimates and Forecasts, 2017 – 2030 (Million)
7.1.6 Musculoskeletal Disorders
7.1.6.1 Musculoskeletal Disorders Market Estimates and Forecasts, 2017 – 2030 (Million)
7.1.7 Others
7.1.7.1 Others Market Estimates and Forecasts, 2017 – 2030 (Million)
Chapter 8 Digital Biomarkers Market: Segment Analysis, by End-Use, 2017 – 2030 (USD Million)
8.1 End-Use Movement Analysis, 2021 & 2030
8.1.1 Healthcare Companies
8.1.1.1 Healthcare Companies Market Estimates and Forecasts, 2017 – 2030 (Million)
8.1.2 Healthcare Providers
8.1.2.1 Healthcare ProvidersMarket Estimates and Forecasts, 2017 – 2030 (Million)
8.1.3 Payers
8.1.3.1 Payers Market Estimates and Forecasts, 2017 – 2030 (Million)
8.1.4 Others
8.1.4.1 Others Market Estimates and Forecasts, 2017 – 2030 (Million)
Chapter 9 Digital Biomarkers Market: Regional Market Analysis, by type, clinical practice, therapeutic area, and end-Use, 2017 – 2030 (USD Million)
9.1 Market Size, & Forecasts, Volume, and Trend Analysis, 2017 to 2030
9.2 North America
9.2.1 North America Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.2.2 U.S.
9.2.2.1 U.S. Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.2.3 Canada
9.2.3.1 Canada Digital Biomarkers Market Estimates and Forecasts, 2017 -2030 (Million)
9.3 Europe
9.3.1 Europe Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.3.2 U.K.
9.3.2.1 U.K. Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.3.3 Germany
9.3.3.1 Germany Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.3.4 Netherlands
9.3.4.1 Netherlands Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.3.5 Italy
9.3.5.1 Italy Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.3.6 Switzerland
9.3.6.1 Switzerland Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.4 Asia Pacific
9.4.1 Asia Pacific Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.4.2 Japan
9.4.2.1 Japan Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.4.3 China
9.4.3.1 China Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.4.4 Australia
9.4.4.1 Australia Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.4.5 India
9.4.5.1 India Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.4.6 South Korea
9.4.6.1 South Korea Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.5 Latin America
9.5.1 Latin America Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.5.2 Brazil
9.5.2.1 Brazil Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.5.3 Mexico
9.5.3.1 Mexico Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.6 MEA
9.6.1 MEA Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.6.2 South Africa
9.6.2.1 South Africa Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
9.6.3 Israel
9.6.3.1 Israel Digital Biomarkers Market Estimates and Forecasts, 2017 – 2030 (Million)
Chapter 10 Company Profiles
10.1 ActiGraph LLC
10.1.1 Company Overview
10.1.2 Financial Performance
10.1.3 Product Benchmarking
10.1.4 Strategic Initiatives
10.2 AliveCor Inc
10.2.1 Company Overview
10.2.2 Financial Performance
10.2.3 Product Benchmarking
10.2.4 Strategic Initiatives
10.3 Koneksa
10.3.1 Company Overview
10.3.2 Financial Performance
10.3.3 Product Benchmarking
10.3.4 Strategic Initiatives
10.4 Amgen Inc.
10.4.1 Company Overview
10.4.2 Financial Performance
10.4.3 Product Benchmarking
10.4.4 Strategic Initiatives
10.5 Biogen Inc.
10.5.1 Company Overview
10.5.2 Financial Performance
10.5.3 Product Benchmarking
10.5.4 Strategic Initiatives
10.6 Altoida Inc
10.6.1 Company Overview
10.6.2 Financial Performance
10.6.3 Product Benchmarking
10.6.4 Strategic Initiatives
10.7 IXICO plc
10.7.1 Company Overview
10.7.2 Financial Performance
10.7.3 Product Benchmarking
10.7.4 Strategic Initiatives
10.8 Adherium Limited
10.8.1 Company Overview
10.8.2 Financial Performance
10.8.3 Product Benchmarking
10.8.4 Strategic Initiatives
10.9 Empatica Inc
10.9.1 Company Overview
10.9.2 Financial Performance
10.9.3 Product Benchmarking
10.9.4 Strategic Initiatives
10.10 Huma
10.10.1 Company Overview
10.10.2 Financial Performance
10.10.3 Product Benchmarking
10.10.4 Strategic Initiatives
10.11 VivoSense
10.11.1 Company Overview
10.11.2 Financial Performance
10.11.3 Product Benchmarking
10.11.4 Strategic Initiatives
10.12 ResApp (Pfizer)
10.12.1 Company Overview
10.12.2 Financial Performance
10.12.3 Product Benchmarking
10.12.4 Strategic Initiatives



★調査レポート[世界のデジタルバイオマーカー市場2022-2030:種類別(ウェアラブル、モバイルアプリケーション、センサー)、臨床診療別、治療領域別、最終用途別、地域別] (コード:GRV22NV029)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のデジタルバイオマーカー市場2022-2030:種類別(ウェアラブル、モバイルアプリケーション、センサー)、臨床診療別、治療領域別、最終用途別、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆